Muhammad Hanif

Dr. Muhammad Hanif

University of Auckland, School of Chemical Sciences
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
Muhammad HanifMuhammad Hanif
Muhammad Hanif
AKAfsar Khan
Afsar Khan
Muhammad HanifMuhammad Hanif
Muhammad Hanif
UFUmar Farooq
Umar Farooq
SPShagufta Perveen
Shagufta Perveen
Aim of the Review.To grasp the fragmented information available on the botany, traditional uses, phytochemistry, pharmacology, and toxicology ofOlea europaeato explore its therapeutic potential and future research opportunities.Material and Methods.All the available information onO. europaeawas collected via electronic search (using Pubmed, Scirus, Google Scholar, and Web of Science) and a library search.Results.Ethnomedical uses ofO. europaeaare recorded throughout the world where it has been used to treat various ailments. Phytochemical research had led to the isolation of flavonoids, secoiridoids, iridoids, flavanones, biophenols, triterpenes, benzoic acid derivatives, isochromans, and other classes of secondary metabolites fromO. europaea. The plant materials and isolated components have shown a wide spectrum ofin vitroandin vivopharmacological activities like antidiabetic, anticonvulsant, antioxidant, anti-inflammatory, immunomodulatory, analgesic, antimicrobial, antiviral, antihypertensive, anticancer, antihyperglycemic, antinociceptive, gastroprotective, and wound healing activities.Conclusions. O. europaeaemerged as a good source of traditional medicine for the treatment of various ailments. The outcomes of phytochemical and pharmacological studies reported in this review will further expand its existing therapeutic potential and provide a convincing support to its future clinical use in modern medicine.

1 October 2014 in Drug Discovery Today
Verified
Journal Article
Closed access
Muhammad HanifMuhammad Hanif
Muhammad Hanif
MBMaria Babak
Maria Babak
CHChristian Hartinger
Christian Hartinger

7 December 2020 in ACS Nano
Verified
Journal Article
Closed access
DWDengshuai Wei
Dengshuai Wei
YYYingjie Yu
Yingjie Yu
XZXingcai Zhang
Xingcai Zhang
YWYongheng Wang
Yongheng Wang
HCHao Chen
Hao Chen
HXHaihua Xiao
Haihua Xiao

7 February 2018 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
Muhammad HanifMuhammad Hanif
Muhammad Hanif
CHChristian Hartinger
Christian Hartinger
Despite the severe side effects and the emergence of drug resistance, the use of DNA-targeting platinum drugs remains strong either alone or in a combination chemotherapy regimen. New strategies and formulations are being explored in the design of anticancer metal complexes that exhibit nonclassical modes of action, selectively hit precise biomolecular targets or are even able to induce immunogenic anticancer activity. These developments will ameliorate the systemic toxicity of metal-based drugs and widen the range of treatable cancers.

14 February 2013 in Chemical Science
Verified
Journal Article
Closed access
PDF file
SMSamuel M. Meier-Menches
Samuel M. Meier-Menches
Muhammad HanifMuhammad Hanif
Muhammad Hanif
ZAZenita Adhireksan
Zenita Adhireksan
VPVerena Pichler
Verena Pichler
MNMaria Novak
Maria Novak
CHChristian Hartinger
Christian Hartinger
A novel series of organometallic antitumour agents based on RuII and OsII complexes containing N-substituted 2-pyridinecarbothioamides (PCAs) has been synthesized and characterized. To the best of our knowledge, this is the first report of organometallic anticancer compounds with an S,N-bidentate ligand system. While the ligands showed activity as gastric mucosal protectants and low acute toxicity in vivo (J. Med. Chem., 1990, 33, 327–336), coordination leads to highly antiproliferative metallodrugs, depending on lipophilicity and steric demand, in colon carcinoma and non-small lung cancer cell lines with intrinsic chemoresistances. The most lipophilic and smallest congeners are the most effective with IC50 values in the low micromolar range. This new family of potential metallodrugs features exceptional stability in hydrochloric acid (60 mM), characterized by complete suppression of hydrolysis and low reactivity towards biological nucleophiles. Therefore, their unexpected aqueous chemistry renders this family of antiproliferative agents suitable for oral administration. An unprecedented feature is their ability to form transient thioketone-bridged dimers in aqueous solution upon hydrolysis, which is believed to minimize deactivation by biological nucleophiles. However, the biological effect seems to be caused by the monomer as observed with crystallographic studies of the nucleosome core particle (NCP), which revealed that [chlorido(η6-p-cymene)(N-phenyl-2-pyridinecarbothioamide)osmium(II)] chloride and [chlorido(η6-p-cymene)(N-fluorophenyl-2-pyridinecarbothioamide)osmium(II)] chloride react at two types of binding sites on the histone proteins. The adducts form at histidine side chains located on the nucleosome surface and the inner cleft of the nucleosome in the midst of an extensive histone–histone interface, suggesting interference with chromatin activity as a possible mode of action of these compounds. Additionally, ligand-based S → O exchange allows for a potential dual-mode of action by targeting DNA (J. Med. Chem., 2009, 52, 7753–7764). The quantitative estimates of drug-likeness (QED) for this family of compounds revealed a similar drug-likeness compared to erlotinib, tamoxifen, imatinib and sorafenib.

1 May 2013 in Synthetic Metals
Verified
Journal Article
Closed access
Habib ULLAHHabib ULLAH
Habib ULLAH
KAKhurshid Ayub
Khurshid Ayub
Zakir UllahZakir Ullah
Zakir Ullah
Muhammad HanifMuhammad Hanif
Muhammad Hanif
RNRaziq Nawaz
Raziq Nawaz
SBSalma Bilal
Salma Bilal